Monitor endometrioma size of participants: CDSCO panel tells Abbott India on Dydrogesterone - Video

Published On 2023-06-14T14:29:42+05:30 | Updated On 14 Jun 2023 2:55 PM IST

Overview

Suggesting monitoring the size of the endometrioma of participating subjects during the clinical trial, the Subject Expert Committee (SEC) functional under the Central Drug Standard Control Organization (CDSCO) has granted approval to the drug major Abbott India to conduct the Phase III clinical trial and bioequivalence (BE) study of Dydrogesterone Sustained Release Suggesting monitoring the size of the endometrioma of participating subjects during the clinical trial, the Subject Expert Committee (SEC) functional under the Central Drug Standard Control Organization (CDSCO) has granted approval to the drug major Abbott India to conduct the Phase III clinical trial and bioequivalence (BE) study of Dydrogesterone Sustained Release Tablets 20mg, an orally active progestogen that acts directly on the uterus, producing a complete secretory endometrium in an estrogen-primed uterus.

For more details, check out the full story on the link below:

Monitor endometrioma size of participants: CDSCO panel tells Abbott India on Dydrogesterone

Speakers

Isra Zaman

B.Sc Life Sciences, M.Sc Biotechnology, B.Ed

Isra Zaman is a Life Science graduate from Daulat Ram College, Delhi University, and a postgraduate in Biotechnology from Amity University. She has a flair for writing, and her roles at Medicaldialogues include that of a Sr. content writer and a medical correspondent. Her news pieces cover recent discoveries and updates from the health and medicine sector. She can be reached at editorial@medicaldialogues.in.